

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Luzhu Biotechnology Co., Ltd.
北京綠竹生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2480)

INSIDE INFORMATION
COMPLETION OF THE H SHARE FULL CIRCULATION
BY THE COMPANY

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated December 28, 2023, January 17, 2024 and January 29, 2024 in relation to among others, the approval by CSRC of the Application and the listing approval granted by the Stock Exchange regarding the implementation of the H share full circulation programme of the Company (the “**Announcements**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board is pleased to announce that the conversion of an aggregate of 59,729,296 Unlisted Shares of the Company was completed on January 31, 2024 and the listing of such Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on February 1, 2024.

SHAREHOLDING STRUCTURE OF THE COMPANY BEFORE AND AFTER THE COMPLETION OF THE CONVERSION AND LISTING

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is set out below:

Class of Shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	Number of Shares	Approximate percentage	Number of Shares	Approximate percentage
Unlisted Shares	59,729,296	29.50%	–	–
H Shares	142,719,736	70.50%	202,449,032	100.00%
Total	202,449,032	100.00%	202,449,032	100.00%

Among the 59,729,296 Converted H Shares, (i) 1,434,783 Converted H Shares owned by Beijing Xinyin Xinghong Equity Investment Partnership (Limited Partnership) (北京信銀興弘股權投資合夥企業(有限合夥)) are subject to a statutory restriction on transfer for a period of one year from the date of listing of H shares of the Company as disclosed in the prospectus of the Company dated April 25, 2023 (“**Statutory Lock-up**”); and (ii) on top of the pre-existing Statutory Lock-up, 58,294,513 Converted H Shares owned by Mr. KONG Jian (孔健), one of the controlling shareholders of the Company, are subject to a voluntary non-disposal undertaking of Mr. KONG for a period of two years from the date of completion of the Conversion and Listing as disclosed in the Announcements.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, January 31, 2024

As at the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Mr. LEUNG Wai Yip, Mr. LIANG Yeshe and Ms. HOU Aijun as independent non-executive Directors.